Common uses of Cycrin (medroxyprogesterone acetate)
Cycrin is a progestin, a lab-made version of the naturally occurring hormone progesterone. It is prescribed for two main gynecologic conditions: abnormal uterine bleeding due to hormonal imbalance and secondary amenorrhea (the absence of menstrual periods in someone who previously menstruated). In both scenarios, Cycrin supplies progesterone-like activity to stabilize the uterine lining (endometrium), helping to create a predictable withdrawal bleed after the medication is stopped.
Another well-established use is as part of hormone therapy in postmenopausal adults who are taking systemic estrogens. Estrogen alone can cause overgrowth of the uterine lining; adding a progestin such as Cycrin for part of each month helps reduce the risk of endometrial hyperplasia. Your clinician will tailor the regimen to your personal risk profile and treatment goals.
Cycrin is not a birth control pill and should not be relied upon for contraception. The injectable form of medroxyprogesterone (Depo-Provera) is used for contraception, but that is a different product and dosing method. If you need pregnancy prevention, discuss reliable contraceptive options that can be used alongside or instead of Cycrin, depending on your plan of care.
Cycrin dosage and direction
Always follow your prescriber’s instructions, which may differ from general ranges. Cycrin tablets are commonly taken by mouth with or without food, preferably at the same time each day to support consistent hormone levels. Swallow with water; do not crush unless your pharmacist confirms it is safe for your specific tablet.
Typical dosing ranges (for reference only):
• Abnormal uterine bleeding due to hormonal imbalance: 5–10 mg once daily for 5–10 days. A withdrawal bleed usually occurs within a few days after the last dose. Your clinician may schedule this course during a specific cycle window (for example, days 16–25).
• Secondary amenorrhea: 5–10 mg once daily for 5–10 days, often repeated in cycles to help trigger predictable withdrawal bleeding.
• Endometrial protection during estrogen therapy (postmenopause): 5–10 mg once daily for 12–14 days of each 28-day cycle, combined with your prescribed estrogen.
Some plans use alternate-day dosing or different start days to match your symptoms, lab results, and response to therapy. If you have kidney or liver issues, migraines, or a history of blood clots, your dosing and monitoring schedule may be adjusted. Do not change the dose, start, or stop Cycrin without checking with your healthcare professional.
During therapy, track bleeding patterns, cramps, headaches, mood, and any spotting, and share this diary at follow-up visits. This real-world information helps your clinician fine-tune the dose, duration, and timing to optimize benefits and minimize side effects.
Precautions before taking Cycrin
Tell your clinician about your complete medical history, including previous blood clots, stroke, heart disease, high blood pressure, migraine (especially with aura), high cholesterol, diabetes, obesity, smoking status, depression, liver disease, gallbladder disease, kidney disease, seizures, and any known clotting disorders. These factors can influence the safety of progestin therapy, particularly if you also use estrogen.
Pregnancy and lactation: Do not take Cycrin if you are pregnant or suspect pregnancy. Cycrin is not a test for pregnancy and should not be used to diagnose pregnancy. If you are breastfeeding, ask your clinician about timing and suitability; progestins pass into breast milk in small amounts, and recommendations depend on dose, timing, and your infant’s health.
Surgery and immobility: If you will be immobilized for a prolonged period or undergo major surgery, discuss whether to pause hormone therapy beforehand to reduce the risk of blood clots. If you develop sudden leg swelling, chest pain, shortness of breath, or vision changes, seek emergency care immediately.
Who should not take Cycrin? Contraindications
Avoid Cycrin if you have any of the following unless your specialist has advised otherwise for a specific indication: known or suspected pregnancy; undiagnosed abnormal genital bleeding; active or history of blood clots (thrombophlebitis, deep vein thrombosis, pulmonary embolism), stroke, or certain heart conditions; significant liver disease or liver tumors; known hypersensitivity to medroxyprogesterone or any tablet component; and known or suspected hormone-sensitive cancers unless used under oncology guidance.
If you are using estrogen plus progestin for postmenopausal hormone therapy, be aware of boxed warnings regarding increased risks of cardiovascular events, breast cancer, and probable dementia in certain age groups. Use the lowest effective dose for the shortest appropriate duration, with periodic reevaluation.
Possible side effects of Cycrin
Many people tolerate Cycrin well, especially when used for short courses. Common side effects include headache, breast tenderness, bloating or fluid retention, nausea, abdominal cramps, changes in mood or libido, dizziness, fatigue, acne or oily skin, and changes in bleeding patterns (spotting, lighter or heavier withdrawal bleeding, or temporary cycle irregularity). These often improve as your body adapts or after the medication course ends.
Less common but more serious effects can include elevated blood pressure, significant mood changes or depression, jaundice or other signs of liver trouble, migraine with new neurological symptoms, and allergic reactions such as rash, hives, facial swelling, or difficulty breathing. Combining estrogen and progestin may increase the risk of blood clots, stroke, or heart attack in susceptible individuals. Know your personal risk factors and review them regularly with your clinician.
Seek urgent care for warning signs: sudden severe headache, confusion, weakness or numbness on one side of the body, sudden vision loss or double vision, chest pain, shortness of breath, coughing blood, painful leg swelling, or severe abdominal pain. Report persistent or heavy bleeding between courses, postmenopausal bleeding while on therapy, or any symptom that is unusual for you.
Cycrin drug interactions
Medroxyprogesterone is metabolized largely by CYP3A4. Strong CYP3A4 inducers can lower Cycrin levels and reduce effectiveness. Examples include rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital, primidone, topiramate, and herbal St. John’s wort. CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, and grapefruit products) may raise levels and side-effect risk. If you start or stop any of these, your dose and monitoring may need adjustment.
Progestins can also affect glucose tolerance and fluid balance; monitor closely if you take insulin or oral diabetes medicines, diuretics, or have heart/kidney issues. Anticoagulants (such as warfarin) may require closer INR monitoring when hormones are initiated or changed. Tell your clinician about all prescription and over-the-counter drugs, vitamins, and supplements, including hormonal contraceptives, thyroid hormones, antiepileptics, HIV/HCV treatments, and herbal products.
Missed dose: what to do
If you miss a dose of Cycrin, take it as soon as you remember that same day. If it is nearly time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double up to “catch up.” If you miss more than one dose or are following a cyclic regimen and are unsure where to restart, contact your clinician or pharmacist for guidance. Keep a simple reminder system (phone alarm or pillbox) to support consistency.
Overdose: signs and immediate steps
An acute overdose of oral medroxyprogesterone is uncommon and typically not life-threatening. Possible symptoms include nausea, vomiting, breast tenderness, drowsiness, and unexpected bleeding. If someone takes more than prescribed, call your clinician, local poison control, or seek medical attention for personalized advice—especially in children, during pregnancy, or if severe symptoms occur. Supportive care is usually all that is required.
Storage and handling
Store Cycrin tablets at room temperature, ideally 20–25°C (68–77°F), protected from moisture and excessive heat. Keep the medication in its original container with the child-resistant cap closed tightly. Do not store in the bathroom. Keep out of sight and reach of children and pets. Do not use tablets past the expiration date or if the packaging is damaged. Dispose of unused medication through a take-back program or according to pharmacist instructions—do not flush unless specifically directed.
U.S. sale and prescription policy for Cycrin
In the United States, Cycrin (medroxyprogesterone acetate tablets) is a prescription medicine. Traditionally, obtaining it requires a clinician’s evaluation and a written or electronic prescription sent to your pharmacy. Many patients now prefer streamlined, telehealth-supported options that still comply with federal and state regulations and maintain appropriate clinical oversight.
HealthSouth Rehabilitation Hospital of Las Vegas offers a legal and structured solution for acquiring Cycrin without a formal prescription, using a compliant, pharmacist-guided process where permitted by law. Their workflow includes a brief clinical intake, safety screening, and ongoing support to help ensure appropriate use. Availability may vary by state, and additional documentation may be required based on your health profile. If you’re a suitable candidate, you can buy Cycrin without prescription through HealthSouth Rehabilitation Hospital of Las Vegas with discreet shipping, transparent pricing, and access to pharmacists for questions. This service is not a substitute for individualized medical care—consult your healthcare professional for diagnosis, personalized dosing, and long-term management.
